Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Temozolomide Stories

2013-12-02 16:23:39

Company invites Main Street and Wall Street investors to attend interactive real-time virtual conference NEW YORK, Dec. 2, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI), developer of advanced cancer therapeutics, today announced that Jeffrey Bacha, B.Sc., MBA, president & CEO, will present at RetailInvestorConferences.com. DelMar is developing VAL-083 in U.S. and China to treat aggressive cancers. DelMar's lead drug, VAL-083, is being developed in the U.S. to treat...

2013-11-26 08:27:27

Additional Preclinical Studies Demonstrate Potential for Intravenous Administration of Toca 511 and Use in Combination with Temozolomide and Radiation SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Tocagen Inc. today announced that interim clinical data from two ongoing Phase I investigational studies presented at the Society for Neuro-Oncology (SNO) Annual Meeting in San Francisco showed that Toca 511 administration followed by courses of oral Toca FC was safe and well tolerated in 60...

2013-11-22 08:23:18

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 22, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced the presentation of interim data from a Phase 1/2 clinical trial for VAL-083 in recurrent glioblastoma (GBM) at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18(th) Annual Society for Neuro-Oncology (SNO) meeting in San Francisco. Enrollment in the...

2013-11-22 08:23:09

SAN DIEGO, Nov. 22, 2013 /PRNewswire/ -- Tocagen Inc. today announced that six presentations on Toca 511 will be given at the Society of Neuro-Oncology (SNO) Annual Meeting, including interim clinical data from two ongoing Phase I investigational studies, which show that, to date, Toca 511 administration followed by oral courses of Toca FC is safe and well tolerated, and demonstrated antitumor activity in some patients with high grade glioma (HGG). HGG includes glioblastoma multiforme (GBM),...

2013-11-18 08:30:09

Neuro-Oncology experts from around the world will gather in San Francisco where data supporting the role of Tumor Treating Fields (TTFields) in treating recurrent glioblastoma brain tumors will be presented ST. HELIER, Jersey, Nov. 18, 2013 /PRNewswire/ -- Novocure announced today that 15 preclinical and clinical abstracts describing the latest aspects of NovoTTF(TM) Therapy will be presented at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO), which is...

2013-11-14 08:33:50

VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 14, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" and "DelMar Pharma") today announced that the Company will present interim clinical trial data for VAL-083 in glioblastoma at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO) being held in conjunction with the 18(th) Annual Society for Neuro-Oncology (SNO) meeting. The WFNO/SNO meeting will take place November 21(st)...

2013-11-11 04:21:07

-Study Features THC and CBD as the Primary Cannabinoids- LONDON, Nov. 11, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today it has commenced a Phase 1b/2a clinical trial for the treatment of Recurrent Glioblastoma Multiforme (GBM). Glioma describes any tumor that arises from the glial tissue...

2013-10-09 08:27:04

Glioblastoma multiforme (GBM) Phase 1b clinical trial is ongoing for VAL-083, a chemotherapy that has been well-studied by the National Institutes of Health VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 9, 2013 /PRNewswire/ -- The president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma" or "DelMar") Jeffrey Bacha spoke to Life Science IP Review (LSIPR) about developing new intellectual property (IP) for their lead drug candidate, VAL-083, a new therapy in...

2013-09-30 14:19:00

Results from a clinical trial of a new treatment for glioblastoma suggest that researchers may have found a new approach to treating this most aggressive of brain tumors, as well as a potential new biological marker than can predict the tumor's response to treatment. Presenting the research to the 2013 European Cancer Congress (ECC2013) today (Monday), Professor Wolfgang Wick will say that combining radiotherapy with an anti-cancer drug called APG101 – a fusion protein similar to an...

2013-09-19 08:28:34

Glioblastoma is the most common form of brain cancer, and DelMar is developing VAL-083 in the U.S. and China to treat aggressive cancers VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 19, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar Pharma" or "DelMar") today announced a discussion on CEOLIVE.TV by Jeffrey Bacha, president and CEO of DelMar Pharma, a cancer-focused company developing new therapies for patients with little to no treatment options....